Garde Noguera, J., Jantus-Lewintre, E., Gil-Raga, M., Evgenyeva, E., Maciá Escalante, S., Llombart-Cussac, A., & Camps Herrero, C. (2017). Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol.

Garde Noguera, Javier, Eloisa Jantus-Lewintre, Mireia Gil-Raga, Elena Evgenyeva, Sonia Maciá Escalante, Antonio Llombart-Cussac, and Carlos Camps Herrero. "Role of RAS Mutation Status As a Prognostic Factor for Patients With Advanced Colorectal Cancer Treated With First-line Chemotherapy Based On Fluoropyrimidines and Oxaliplatin, With or Without Bevavizumab: A Retrospective Analysis." Mol Clin Oncol 2017.

Garde Noguera, Javier, et al. "Role of RAS Mutation Status As a Prognostic Factor for Patients With Advanced Colorectal Cancer Treated With First-line Chemotherapy Based On Fluoropyrimidines and Oxaliplatin, With or Without Bevavizumab: A Retrospective Analysis." Mol Clin Oncol 2017.